Role as a biomarker for TB prevention and drug development
- Actiphage is a detection technology that has been shown to identify patients at greatest risk of progression to TB disease.
- Actiphage could potentially be used for a “rule-in” preventive therapy diagnostic test where a positive test result indicates that TB will probably develop.
- Actiphage coupled with preventive drug treatment could potentially be an important step to accelerate progress towards TB elimination.
- Actiphage could potentially be an important new tool in public health, allowing scale-up of contact tracing strategies and mass test-and-treat campaigns.
Role of a biomarker for TB prevention in vaccine development
- Actiphage supports TB vaccine development as a biomarker indicating signs of the prospective risk of developing TB.
- Actiphage could potentially allow a “rule-out” vaccine diagnostic whereas a negative result provides confidence that a patient is unlikely to develop tuberculosis disease and is a candidate for vaccination.
- Actiphage may accelerate vaccine research and development in TB as a companion diagnostic by allowing investigators to detect signals of efficacy at earlier stages of development.
TB clinical trial collaborations
Advancing research and development to create next generation TB treatment regimens through innovative partnerships and collaborations are critical to bringing new therapies to market. Here are some exciting initiatives.